Strong Revenue Growth
The company reported a 19% revenue growth over 2024, reaching $33.3 million in the third quarter of 2025.
Increased Gross Margin
Gross margin improved to 66.1% from 58.4% in the same period in 2024, attributed to favorable sales mix and greater scale.
Positive Net Income
The company achieved a net income of $1.3 million, or 1¢ per share, compared to a net loss of $5 million in the comparable 2024 period.
Successful Product Launches
The launch of new products like Collagen X and growth in core biologics product family, despite being below long-term expectations, contribute to future growth potential.
Pending Asset Sale
The sale of non-core assets to Companion Spine is expected to provide $19.2 million, strengthening the company's financial position and focusing on core business.